Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

Wahle, Raul Carlos; Perez, Renata M.; Pereira, Patrícia Fucuta; Oliveira, Elze Maria Gomes; Emori, Christini Takemi; Uehara, Silvia Naomi de Oliveira; Silva, Ivonete Sandra de Souza; Silva, Antônio Eduardo Benedito; Ferraz, M.L.G.

doi:10.1016/j.bjid.2015.04.003

Cited by 16 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk of late HBV reactivation had already been demonstrated in a small study by Wahle et al of a cohort of 10 HCV/HBV coinfected patients from a hemodialysis center. The study showed that after HCV treatment with pegylated-interferon and ribavirin, most HBV reactivations occurred at a late stage (mean time, 22 ± 9 months) [23].…”

Section: Discussionmentioning

confidence: 97%

Hepatitis B reactivation after HCV treatment with sofosbuvir/ledipasvir in a HIV-coinfected patient with previous positive anti-HBs antibody: a case report and a review of literature

Soeiro¹,

Tavares²,

Castro³

2018

HIV & AIDS Review

View full text Add to dashboard Cite

Chronic hepatitis B (HBV) and C (HCV) coinfection are frequently observed in clinical practice. The interaction between HCV and HBV is complex and not completely understood, and usually results in the suppression of hepatitis B replication by HCV superinfection or coinfection. Cases of hepatitis B reactivation during and after HCV treatment with direct acting antivirals (DDA) have been described, and it is recommended to screen all patients starting DAA therapy for HBV infection markers and to monitor those that have positive markers of HBV infection. HBs antigen (HBsAg) positivity is the main risk factor for HBV reactivation, and this phenomenon is rarer in those with "resolved" HBV infection (negative HBsAg, positive antiHBc antibody (HBcAb) and anti-HBs antibody (HBsAb) positive or negative). The authors present a case of HBV reactivation after HCV treatment with sofosbuvir/ ledipasvir that occurred in a 54-year-old male that was HIV-coinfected and had "resolved" hepatitis B infection (negative HBsAg, positive HBcAb and positive HBsAb). Our case reinforces the need to screen all patients who will start DAA therapy for hepatitis C infection, and alerts clinicians to the need to closely monitor patients with evidence of previous HBV infection no only during treatment but also after HCV treatment with DAAs.

show abstract

Section: Discussionmentioning

confidence: 97%

Hepatitis B reactivation after HCV treatment with sofosbuvir/ledipasvir in a HIV-coinfected patient with previous positive anti-HBs antibody: a case report and a review of literature

Soeiro¹,

Tavares²,

Castro³

2018

HIV & AIDS Review

View full text Add to dashboard Cite

show abstract

“…Between 2 and 10% of anti-HCV-positive patients also test positive for HBsAg, while 5-20% of patients with chronic HBV infection test positive for anti-HCV antibodies [68]. It has been reported that HBV/HCV coinfection leads to more severe liver disease and a higher prevalence of liver cancer than noninfection [69], but an inverse relationship between the replication of each virus within some co-infected patients has been noted [70][71][72][73][74]. Hepatitis B virus-Hepatitis C virus co-infection Table 2.…”

Section: Monocytes/macrophages In Hbv/hcv Co-infectionmentioning

confidence: 99%

The Role of Monocytes/Macrophages in HBV and HCV Infection

Li¹,

Tu²

2017

Biology of Myelomonocytic Cells

View full text Add to dashboard Cite

Monocytes/macrophages constitute the irst line of defence for external intrusion or infection. Circulatory monocytes represent about 10% of leukocytes in human blood and resident macrophages are distributed in a variety of tissues and organs to maintain body homeostasis. But relatively litle is known about the consequences of chronic viral infections on monocytes. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are the most important causes of chronic liver diseases, which may develop to serious and fatal liver pathology, including liver cirrhosis and hepatocellular carcinoma. Whether HBV and HCV infections are cleared or persist is determined by host immune responses. Viral replication takes place inside hepatocytes as soon as infection begins. The secretion of infectious virions or virus proteins can persist for decades at high rates. Chronic infections with HBV and HCV are the result of inefective anti-viral immune response towards the virus. Interacting with virions or virus proteins, monocytes/macrophages play an important function in the disease process. The role of monocytes/macrophages in HBV and HCV infections or co-infections is discussed in this chapter.

show abstract

“…Wahle et al evaluated the HBV reactivation after HCV treatment in 10 hemodialysis patients with HBV/HCV coinfection (HBV DNA lower than 2,000 IU/mL) treated with interferon-alpha and followed them up at least 36 months after HCV treatment (16). HBV reactivation during followup was observed in 6/10 patients including 5/6 patients with SVR.…”

Section: Hbv Reactivation During Ifn-based Therapy For Hcvmentioning

confidence: 99%

Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA

Pawłowska

Domagalski

2017

Hepat Mon

View full text Add to dashboard Cite

The exact number of HBV/HCV co-infected patients is unknown. In many cases of HBV/HCV co-infection, HCV inhibits replication of HBV. After treatment and eradication of the dominant virus, the other one may then become active. The overall dominant effect appears to be hepatitis C over hepatitis B. Therefore, when planning treatment for eradication of HCV, the risk of HBV reactivation should be taken into account. In interferon-based therapies of patients with HBV/HCV co-infection, some cases of HBV reactivation without hepatitis were observed because IFN is effective against both viruses. In contrast, DAA treatment of hepatitis C in HBV/HCV co-infection is not well established. Currently, no clinical trials have been published regarding treatment of HBV/HCV co-infected patients with HCV DAA therapy. There is several research on HCV DAA therapy in HBV/HCV co-infection, which describes cases of HBV reactivation during and after DDA therapy for HCV. Result of the first available studies demonstrated that patients with HBV/HCV co-infection treated with DAA against HCV should be monitored for HBV reactivation during and after DAA treatment, even though HBV may be inactive at the time of treatment initiation.

show abstract

Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

Cited by 16 publications

References 18 publications

Hepatitis B reactivation after HCV treatment with sofosbuvir/ledipasvir in a HIV-coinfected patient with previous positive anti-HBs antibody: a case report and a review of literature

Hepatitis B reactivation after HCV treatment with sofosbuvir/ledipasvir in a HIV-coinfected patient with previous positive anti-HBs antibody: a case report and a review of literature

The Role of Monocytes/Macrophages in HBV and HCV Infection

Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA

Contact Info

Product

Resources

About